A Registry of AL Amyloidosis (ReAL)

Fondazione IRCCS Policlinico San Matteo di Pavia5,000 enrolled

Overview

The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.

Thanks to this registry, it will be possible to collect data at diagnosis and during follow up, in order to be able to describe the natural history of AL amyloidosis in a real-world setting and to define and validate prognostic models, response and relapse criteria applicable at any point of the disease.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

AL Amyloidosis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. diagnosis of systemic AL amyloidosis; 2. treatment-naïve (pre-treatment data collected at participating center available for retrospective part); 3. age ≥18 years; 4. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted); 5. planned (or ongoing) follow-up at participating center. Exclusion Criteria: 1. non-AL amyloidosis; 2. previous treatment for AL amyloidosis.

Locations (1)

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

RECRUITING

Outcomes

Primary Outcomes

Creation of a registry of patients with AL amyloidosis

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.